ESH 2017 | The challenges facing elderly AML treatment
Lars Bullinger
• 12 Oct 2017
To effectively treat acute myeloid leukemia (AML) in elderly patients, it is important that therapies for the right demographic are researched. In this interview, Lars Bullinger, MD, from Charité University of Medicine, Berlin, Germany, discusses the challenges facing the treatment of elderly AML. Prof. Bullinger details how the genomic structure and mutations present in elderly patients produce challenges when developing treatments and how to overcome these issues. This interview was recorded at the International Conference of Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH).
